Boscia Giacomo, Feo Alessandro, Savastano Alfonso, Viggiano Pasquale, Landini Luca, Clemente Arcangelo, Scotti Giacomo, Grassi Maria Oliva, Parisi Guglielmo, Giancipoli Ermete, Alessio Giovanni, Boscia Francesco, Mastropasqua Rodolfo, Reibaldi Michele, Romano Mario R, Borrelli Enrico
Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 20. doi: 10.1007/s00417-025-06797-7.
The sustained-release intravitreal 0.7 mg dexamethasone implant (DEX implant) (Ozurdex®, Allergan®, an AbbVie Company, North Chicago, Illinois, USA) is widely used to treat various inflammatory retinal disorders. Notably, its application is expanding in the field of vitreoretinal surgery.
We conducted a comprehensive literature search across the Web of Science, PubMed, EMBASE, and ScienceDirect databases for articles related to Ozurdex and its applications in vitreoretinal disorders. Additionally, relevant studies were identified from the reference lists of retrieved articles. Our search was limited to studies written in English or those in other languages that provided an English abstract with sufficient information.
Multiple studies have demonstrated the efficacy and safety of the DEX implant across a broad spectrum of vitreoretinal and post-surgical conditions. Notably, the implant's unique pharmacokinetics remain largely unaffected by the vitrectomized status of the eye, ensuring consistent effectiveness in vitreoretinal surgery. Our research highlights the primary off-label applications of the DEX implant, which include epiretinal membrane (ERM), rhegmatogenous retinal detachment (RRD), post-surgical cystoid macular edema (PSCME), and refractory diabetic macular edema (DME).
This review highlights the increasing role of the DEX implant in vitreoretinal surgery, emphasizing its effectiveness and safety in various surgical and post-surgical settings, while also addressing associated complications.
玻璃体内注射0.7毫克地塞米松缓释植入剂（DEX植入剂）（Ozurdex®，Allergan®，艾伯维公司，美国伊利诺伊州北芝加哥）被广泛用于治疗各种炎症性视网膜疾病。值得注意的是，其应用正在玻璃体视网膜手术领域不断扩展。
我们在Web of Science、PubMed、EMBASE和ScienceDirect数据库中进行了全面的文献检索，以查找与Ozurdex及其在玻璃体视网膜疾病中的应用相关的文章。此外，从检索到的文章的参考文献列表中确定了相关研究。我们的检索仅限于用英文撰写的研究或提供了足够信息的英文摘要的其他语言研究。
多项研究已证明DEX植入剂在广泛的玻璃体视网膜疾病和手术后情况下的有效性和安全性。值得注意的是，该植入剂独特的药代动力学在很大程度上不受眼睛玻璃体切除状态的影响，确保了在玻璃体视网膜手术中的持续有效性。我们的研究突出了DEX植入剂的主要超说明书应用，包括视网膜前膜（ERM）、孔源性视网膜脱离（RRD）、术后黄斑囊样水肿（PSCME）和难治性糖尿病性黄斑水肿（DME）。
本综述强调了DEX植入剂在玻璃体视网膜手术中日益重要的作用，强调了其在各种手术和术后情况下的有效性和安全性，同时也讨论了相关并发症。
